Pulmonary Arterial Hypertension Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight

August 07 07:06 2020
Pulmonary Arterial Hypertension Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight

“Pulmonary Arterial Hypertension Pipeline Insight, 2020”

(Albany, US) DelveInsight launched a new report on Pulmonary Arterial Hypertension Pipeline Insight, 2020.

Pulmonary Arterial Hypertension Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pulmonary Arterial Hypertension market. A detailed picture of the Pulmonary Arterial Hypertension pipeline landscape is provided, which includes the disease overview and Pulmonary Arterial Hypertension treatment guidelines.

The assessment part of the report embraces in-depth Pulmonary Arterial Hypertension commercial assessment and clinical assessment of the Pulmonary Arterial Hypertension pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Arterial Hypertension collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Drugs covered

1. Aurora-GT
2. Ralinepag
3. Bardoxolone Methyl
4. Rodatristat Ethyl
5. Sotatercept
And many others

 

Request for Free Sample: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

 

The key players in Pulmonary Arterial Hypertension market are:

1. United Therapeutics
2. Liquidia Technologies
3. Reata Pharmaceuticals
4. Altavant Sciences
5. Acceleron Pharma
And many others

Key benefits of the report

  • The Pulmonary Arterial Hypertension report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Pulmonary Arterial Hypertension across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Pulmonary Arterial Hypertension therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Pulmonary Arterial Hypertension research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Pulmonary Arterial Hypertension.

“The disease is found to be more common among women as compared to men.”

Request for Free Sample: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

Pulmonary Arterial Hypertension therapeutic market is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors for the Pulmonary Arterial Hypertension treatment. Among these therapeutics endothelin receptor antagonists are most widely used for the treatment of Pulmonary Arterial Hypertension.

LetairisVolibris(GlaxoSmithKline plcGilead Science), Opsumit (Actelion Pharmaceuticals Ltd), and Tracleer (Actelion Pharmaceuticals Ltd) are mostly recommended endothelin receptor antagonists being used for the Pulmonary Arterial Hypertension treatment. These antagonists act by relaxing blood vessels and inhibiting proliferation and remodelling of blood vessels. LetairisVolibris (GlaxoSmithKline plcGilead Science), which is a selective Endothelin Type-A (ETA) receptor antagonist is the most robust therapeutic as compared to the other endothelin receptor antagonists (ERAs).

Tracleer (Actelion Pharmaceuticals Ltd) is the first endothelin receptor antagonists being approved by the US FDA for treating Pulmonary Arterial Hypertension. Opsumit (Actelion Pharmaceuticals Ltd) is a tissue- targeting endothelin receptor antagonist indicated explicitly for the treatment of pulmonary arterial hypertension (WHO Group I) to delay disease progression. There are large numbers of Prostacyclin/Prostanoids being available for Pulmonary Arterial Hypertension treatment. There are very few numbers of drugs targeting phosphodiesterase for the treatment of Pulmonary Arterial Hypertension. Revatio (Pfizer) and Adcirca (Eli Lilly and CoGSKUnited Corporation) are the two approved phosphodiesterase inhibitors which act by suppressing high blood pressure by releasing nitric oxide. Revatio (Pfizer) helps in improving pulmonary blood flow. Several studies have reported the use of Adcirca (Eli Lilly and CoGSKUnited Corporation) in improving patient compliance due to once a day dosing.

Overall with the increase in the prevalence of this disease along with the approval of the pipeline therapies, it shall create a positive impact on the Pulmonary Arterial Hypertension treatment market during the forecast period (2020–2030).

Request for Free Sample: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

 

Table of contents

1. Report Introduction

2. Pulmonary Arterial Hypertension 

2.1. Overview

2.2. History 

2.3. Pulmonary Arterial Hypertension Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Pulmonary Arterial Hypertension Diagnosis 

2.6.1. Diagnostic Guidelines

3. Pulmonary Arterial Hypertension Current Treatment Patterns

3.1. Pulmonary Arterial Hypertension Treatment Guidelines

4. Pulmonary Arterial Hypertension – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Pulmonary Arterial Hypertension companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Pulmonary Arterial Hypertension Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Pulmonary Arterial Hypertension Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Pulmonary Arterial Hypertension Late Stage Products (Phase-III)

7. Pulmonary Arterial Hypertension Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pulmonary Arterial Hypertension Discontinued Products

13. Pulmonary Arterial Hypertension Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report? 

14. Pulmonary Arterial Hypertension Key Companies

15. Pulmonary Arterial Hypertension Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Pulmonary Arterial Hypertension Unmet Needs

18. Pulmonary Arterial Hypertension Future Perspectives

19. Pulmonary Arterial Hypertension Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight